Thymidine Kinase 1 in Risk Assessment for Hereditary Breast /Ovarian Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00855998|
Recruitment Status : Unknown
Verified March 2009 by Hadassah Medical Organization.
Recruitment status was: Recruiting
First Posted : March 5, 2009
Last Update Posted : June 3, 2010
|Condition or disease|
|Breast Cancer Ovarian Cancer|
Hereditary breast/ovarian cancer syndrome is associated with mutations in tumor suppressor BRCA1 and BRCA2 genes. Products of these genes play an important role in the repair of DNA double-strand breaks. Mutations in BRCA1 and BRCA2 genes could impair DNA repair. In resting or G1 cells, where the de novo synthesis of DNA precursors is absent, the salvage pathway is the sole provider of deoxyribonucleotides to be used in DNA repair. For this process a sufficient supply of deoxynucleotides and activity of Thymidine Kinase 1 are essential. TK1 is an important component of adaptive response of cells to DNA damage. Mutations in genes directly engaged in the DNA repair process could lead to the accumulation of DNA damage and in turn cause an adaptive cell reaction manifesting as permanently increased Thymidine Kinase 1 activity.
A recently developed new high-sensitive assay DiviTum® allows to investigate the contribution of this enzyme to DNA repair processes and to make a comparison of Thymidine kinase 1 activity in women with normal and impared DNA repair system.
|Study Type :||Observational|
|Estimated Enrollment :||300 participants|
|Official Title:||Thymidine Kinase 1 in Risk Assessment for Hereditary Breast /Ovarian Cancer|
|Study Start Date :||March 2009|
|Estimated Primary Completion Date :||March 2010|
|Estimated Study Completion Date :||March 2011|
With BRCA1 or BRCA2 mutations
Without BRCA1 or BRCA2 mutations
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00855998
|Contact: Tamar Peretz, MD||6777825 ext 00 972 email@example.com|
|Contact: Hadas Lemberg, PhD||6777572 ext 00 972 firstname.lastname@example.org|
|Hadassah Medical Organization||Recruiting|
|Jerusalem, Israel, 91120|
|Contact: Arik Tzukert, DMD 6776095 ext 00 972 2 email@example.com|
|Sub-Investigator: Benjamin Nisman, PhD|